What is the efficacy of gefitinib versus docetaxel as second-line therapy for non–small cell lung cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

The INTEREST trial studied gefitinib versus docetaxel in the second-line setting and found no significant difference in survival (7.6 vs 8 mo). Based on these data, gefitinib was removed from the United States market for use in new patients and was only available by a restricted access program.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!